Abstract
This study examined treatment-emergent (TE) herpetic infections in adult atopic dermatitis (AD) patients receiving ≥1 dose of baricitinib (Bari), an oral selective inhibitor of Janus kinase 1/2. Data were reported from 6 double-blinded, randomised, placebo-controlled (PC) trials and 2 long-term extension studies, within 3 analysis sets: PC, 2-mg–4-mg Bari extended, and All-Bari-AD. Frequency, incidence rate (IR)/ 100 person-years (PYs) and clinical characteristics of TE adverse events (AEs) of herpes simplex (HS) and herpes zoster (HZ) were reported.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.